Table 2. Demographics and baseline characteristics of study participants.

Characteristics	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Age (years)	29	26	28	29	34
Sex	M	M	M	M	M
Height (cm)	182	166	185	183	179
Weight (kg)	76	55	107	91	70
Body mass index	22.9	20.0	31.3	27.2	21.8
Transmission mode	MSM	MSM	Hetero	MSM	Bisexual
Current smoker	No	Yes	Yes	Yes	No
Drinking alcohol	Yes	Yes	Yes	Yes	Yes
Educational attainment	University	University	University	University	University
Marital status	Single	Single	Single	Single	Single
Employment status	Yes	Yes	Yes	Yes	Yes
Living situation	Alone	Alone	With mother	With parents	With mother
Religion	No	No	Yes	Yes	No
Disability	No	No	No	No	No
Other diseases	No	No	No	Lymphoma	No
Years after HIV diagnosis	1 year	2 years	7 years	7 years	8 years
Years of taking ART	1 year	2 years	7 years	7 years	8 years
Initial viral load (copies/mL)	2.25 × 106	1.18 ×106	>1.0 × 107	>1.0 × 107	6.18 × 104
Initial CD4 T-cell count (/mm3)	370	569	129	423	176
Highest viral load (copies/mL)	2.25 × 106	1.18 × 106	>1.0 × 107	>1.0 × 107	6.18 × 104
Nadir CD4 T-cell count (/mm3)	370	569	129	48	176
Baseline viral load (copies/mL)	71.9	<20	<20	<20	<20
Baseline CD4 T-cell count (/mm3)	537	983	1,043	264	680
ART regimen	3TC+ABC+DTG	TAF+FTC+DRV/c	TAF+FTC+DRV/c	3TC+ABC+DTG	3TC+ABC+EFV

MSM, men who have sex with men; HIV, human immunodeficiency virus; ART; antiretroviral therapy; 3TC, lamivudine; ABC, abacavir; DTG, dolutegravir; TAF, tenofovir alafenamide; FTC, emtricitabine; DRV/c, cobicistat-boosted darunavir; EFV, efavirenz.